From SABCS ’21: Neoadjuvant Immunotherapy and the Use of the 21-Gene Signature Test

Peer-Spectives

English - December 14, 2021 18:12 - 11 minutes - 21.2 MB
Science Education obr oncology cancer healthcare medical obroncology peerspectives robertfiglin Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Targeted Therapy and Venclexta Combinations for AML and a Look Ahead to ASH ’21

Next Episode: Frederick Locke, MD of Moffit Cancer Center and Robert Figlin, MD of Cedars-Sinai discuss ZUMA-7, the role of CAR-T in the management of relapsed/refractory B-cell lymphoma, and recent clinical data presented at ASH ‘21

Lajos Pusztai, MD, and Robert Figlin, MD, discuss the practicality of neoadjuvant I-O as demonstrated in KEYNOTE-522 and the application of the Oncotype DX 21-gene signature test in the RxPONDER study, both presented at the 2021 San Antonio Breast Cancer Symposium.